Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.59 |
| ▸ | CTSL | P07711 | 14/20 | 0.59 |
| ▸ | CTSB | P07858 | 10/20 | 0.58 |
| ▸ | CTSK | P43235 | 9/20 | 0.58 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226197 | 1.00 | CTSS (0.59) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL2226204 | 1.00 | CTSS (0.59) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL27684755 | 0.86 | CTSS (0.62) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL17282797 | 0.86 | CTSS (0.62) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL12906609 | 0.86 | ATM (0.61) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL7201466 | 0.83 | CTSS (0.54) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL7201468 | 0.83 | CTSS (0.54) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL6320730 | 0.82 | CTSL (0.60) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL6311222 | 0.82 | CTSL (0.60) | CTSSCTSLCTSBCTSKELANE | |
| SCHEMBL6311227 | 0.82 | CTSL (0.60) | CTSSCTSLCTSBCTSKELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102822192-B | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2015-09-30 | — | — | CN | disclosed |
| EP-2526116-B1 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN | ST GEORGES HOSP MEDICAL SCHOOL (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8637453-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8541363-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2011089396-A2 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE. | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, DPP8 | CTSS 288/4885CTSL 535/4885CTSB 531/4885 |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, PEPD | CTSS 440/4885CTSL 669/4885CTSB 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.